Bausch Health Companies Inc Stock Price, News & Analysis

Bausch Health (NYSE:BHC) has announced the launch of Fraxel FTX™, the next generation of skin resurfacing technology, at the ASLMS 2025 Conference in Orlando. The product will be initially rolled out to US dermatologists and aesthetic professionals, with global expansion planned in coming months.

The new Fraxel FTX™ features dual wavelength fractional laser technology (1550nm and 1927nm), targeting both superficial and deeper skin layers. Key improvements include:

• 20% reduction in handpiece weight and size with integrated cooling
• Intelligent Optical Tracking® with AccuTRAC™ for efficient treatment delivery
• Redesigned console with integrated arm
• New color touch screen interface for personalized treatments

The device is indicated for various dermatological procedures including skin resurfacing, treatment of dyschromia, actinic keratosis, melasma, wrinkles, and scars.

Bausch Health (NYSE:BHC) has filed a supplement to its April 2, 2025 proxy statement, revealing that Carl Icahn and affiliates have acquired cash-settled equity swaps for approximately 90.7 million common shares (24.6%), in addition to their 34.7 million beneficially owned shares (9.4%). This brings Icahn's total economic interest to approximately 34% of outstanding shares.

The company's Board directed a review of Icahn's swap positions and John Paulson's bond holdings. Icahn's swaps were accumulated between May 2021 and September 2023, with a February 2028 maturity date. Paulson, the Board Chairman, holds $50 million in Bausch Health bonds and plans to dispose of these securities to avoid potential conflicts of interest.

In response, Bausch Health implemented a shareholder rights plan (SRP) on April 14, 2025, designed to prevent any entity from acquiring 20% or more of outstanding shares without complying with permitted exemptions.

Bausch Health (NYSE/TSX: BHC) and its subsidiary Salix Pharmaceuticals announced a significant legal victory as the U.S. District Court for the District of Columbia ruled in favor of FDA, Salix, and Teva in a lawsuit filed by Norwich Pharmaceuticals.

The court denied Norwich's motion for preliminary injunction regarding its ANDA for XIFAXAN® (rifaximin) 550 mg. Norwich had challenged FDA's decision to issue tentative approval for their application and the agency's handling of Teva's 180-day exclusivity period. Norwich argued that the FDA's determination would prevent them from marketing their products until at least June 29, 2028, assuming Teva launches its rifaximin product in January 2028.

The District Court granted summary judgment supporting FDA, Salix, and Teva's position, effectively closing the case.

Bausch Health (NYSE:BHC)(TSX:BHC) has announced the adoption of a shareholder rights plan (SRP) effective April 14, 2025. The plan is designed to ensure fair and equal treatment of shareholders during any unsolicited takeover attempts or control acquisitions, including 'creeping' takeovers.

Under the SRP, one right will be attached to each outstanding common share. If triggered, rights holders (except the acquiring party) can purchase additional company shares at a significant discount to market price. The plan includes provisions for 'Permitted Bids' that wouldn't activate the SRP.

The Board emphasizes that this adoption is not in response to any specific takeover proposal or threat. The SRP requires Toronto Stock Exchange acceptance and shareholder ratification within six months of the effective date. If shareholders don't approve the plan, it will terminate along with all outstanding rights.

Bausch Health (NYSE:BHC) and its dermatology division Ortho Dermatologics have launched their 2025 ASPIRE HIGHER Scholarship Program, offering six scholarships worth up to $10,000 each to students affected by dermatologic conditions.

The program includes three Undergraduate Scholar Awards for students pursuing undergraduate or vocational/technical degrees, and three Graduate Scholar Awards for graduate-level students. Applications are open through June 11, 2025, with winners to be announced in July 2025.

Applicants must submit an online application, write an essay about their experience with a diagnosed dermatologic condition and their healthcare provider's role, and provide two reference letters. The scholarships support students attending or applying to two- or four-year colleges, universities, or advanced vocational/technical schools for the 2025-2026 academic year.

Bausch Health, Canada Inc. has signed a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA) for public drug plan coverage of CABTREO, their triple-combination topical treatment for acne vulgaris. The agreement will enable coverage through all Canadian government drug plans, including provincial, territorial, and federal programs.

CABTREO is the first Health Canada-approved triple-combination topical acne treatment combining three mechanisms of action: an antibiotic (clindamycin phosphate), a retinoid (adapalene), and an antibacterial agent (benzoyl peroxide). The prescription gel, administered once daily, is indicated for patients 12 years and older.

Bausch Health (NYSE/TSX: BHC) and its gastroenterology unit Salix Pharmaceuticals have launched 'IBS Symptoms Aren't Black and White: Living in the Gray,' a storytelling campaign for IBS Awareness Month in April 2025.

The initiative aims to highlight the complexities of Irritable Bowel Syndrome (IBS), a condition affecting up to 10% of the global population. The campaign will share patient stories on LinkedIn, focusing on how IBS impacts physical, emotional, social, and professional well-being.

Salix has partnered with the International Foundation for Gastrointestinal Disorders (IFFGD) to reduce stigma and encourage open discussions about IBS symptoms, including diarrhea, difficult bowel movements, abdominal pain, bloating, and urgency. The campaign seeks to empower patients to seek appropriate care and improve how IBS is perceived, diagnosed, and treated.

Bausch Health (NYSE/TSX: BHC) has scheduled the release of its first quarter 2025 financial results for Wednesday, April 30, 2025, after market close. The company will host a conference call and live webcast at 5:00 p.m. U.S. EDT to discuss the quarterly performance and provide a business update. All related materials will be accessible through the Investor Relations section of Bausch Health's website before the call begins.

Bausch Health (NYSE/TSX: BHC) has priced an upsized private offering of $4.4 billion in senior secured notes due 2032 with a 10.000% interest rate through its subsidiary 1261229 B.C. The offering was increased from the initial $4.0 billion target.

The company is also establishing new senior secured credit facilities, including a $500 million 5-year revolving credit facility and a $3.0 billion 5.5-year term loan facility (reduced from $3.4 billion). The proceeds will be used to repay existing credit agreements, redeem various senior secured notes, and for general corporate purposes.

The notes will be secured by a first-priority lien on the issuer's assets, including a 52.5% equity interest in Bausch + Lomb. The offering is expected to close on April 8, 2025, subject to customary conditions.